Edgewise Therapeutics (NASDAQ:EWTX) Price Target Raised to $57.00

Posted by Brenda Bartman on Sep 24th, 2026

Edgewise Therapeutics (NASDAQ:EWTX – Free Report) had its price objective boosted by HC Wainwright from $45.00 to $57.00 in a research note released on Monday morning, Marketbeat Ratings reports. The firm currently has a buy rating on the stock.

Other equities research analysts have also recently issued research reports about the stock. Leerink Partners set a $52.00 price target on shares of Edgewise Therapeutics in a report on Tuesday, June 16th. JPMorgan Chase & Co. increased their target price on Edgewise Therapeutics from $53.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. Raymond James Financial reissued a “strong-buy” rating and issued a $66.00 target price on shares of Edgewise Therapeutics in a report on Monday, June 1st. Guggenheim increased their price objective on Edgewise Therapeutics from $41.00 to $51.00 and gave the company a “buy” rating in a research report on Monday, July 6th. Finally, Wall Street Zen raised Edgewise Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 5th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.33.

View Our Latest Analysis on Edgewise Therapeutics

Edgewise Therapeutics Trading Down 7.8%

NASDAQ:EWTX opened at $41.05 on Monday. Edgewise Therapeutics has a 12 month low of $14.25 and a 12 month high of $48.51. The stock has a market cap of $4.46 billion, a price-to-earnings ratio of -22.19 and a beta of 0.32. The company has a 50-day moving average price of $42.78 and a 200-day moving average price of $37.48.

Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.06). Equities analysts forecast that Edgewise Therapeutics will post -2.09 EPS for the current fiscal year.

Insider Activity at Edgewise Therapeutics

In other news, CEO Kevin Koch sold 17,971 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $43.68, for a total transaction of $784,973.28. Following the transaction, the chief executive officer directly owned 52,488 shares of the company’s stock, valued at $2,292,675.84. This represents a 25.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel John R. Moore sold 5,016 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $43.82, for a total value of $219,801.12. Following the completion of the transaction, the general counsel owned 17,697 shares in the company, valued at approximately $775,482.54. This trade represents a 22.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 238,329 shares of company stock valued at $9,557,529 in the last quarter. 21.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. First Light Asset Management LLC grew its stake in shares of Edgewise Therapeutics by 9.3% during the 2nd quarter. First Light Asset Management LLC now owns 1,095,171 shares of the company’s stock valued at $44,497,000 after purchasing an additional 93,325 shares during the period. Engineers Gate Manager LP bought a new position in shares of Edgewise Therapeutics in the 2nd quarter worth approximately $271,000. Squarepoint Ops LLC purchased a new position in shares of Edgewise Therapeutics in the second quarter worth approximately $230,000. Allianz Asset Management GmbH purchased a new position in shares of Edgewise Therapeutics in the second quarter worth approximately $370,000. Finally, Corient Private Wealth LP bought a new stake in Edgewise Therapeutics during the second quarter valued at approximately $502,000.

About Edgewise Therapeutics

(Get Free Report)

Edgewise Therapeutics, Inc is a clinical-stage biotechnology company focused on developing small-molecule medicines for severe muscle disorders. The company’s research is centered on therapies intended to address the biological mechanisms that contribute to muscle damage and impaired function in diseases affecting skeletal and cardiac muscle.

Edgewise’s lead program is sevasemten (also known as EDG-5506), an orally administered investigational therapy designed to reduce contraction-related muscle injury by selectively modulating fast skeletal muscle contractility.